Study #2025-1685
A phase 1 multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemia or anti-MDS activity of RPT1G in patients with acute myeloid leukemia (AML) and higher-risk (HR) myelodysplastic syndromes/neoplasms (MDS)
MD Anderson Study Status
Enrolling
Treatment Agent
RPT1G
Description
The main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study phase:
Phase I
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?